Skip to content

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial.

Positive OS results with a clinically relevant benefit of ribociclib plus NSAI are demonstrated, consistent with the increasing reduction in recurrence risk, and reinforce the benefit of ribociclib plus NSAI in the adjuvant setting across the broad NATALEE-eligible population.

D. Slamon, G. Hortobagyi, D. Stroyakovskiy et al. · 1 citation
Review Open access Oct 2026

Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis.

ADCs efficacy in metastatic breast cancer was similar across age groups, though data in early-stage disease were limited, and insufficient age- and treatment-stratified toxicity reporting precludes meaningful safety assessment of ADCs in older adults with breast cancer.

Samuel Margolis, T. R. Kalbasi, Yuliya Zektser et al. · 0 citations
Review Open access Sep 2026

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort

Background In the global phase III TROPION-Breast01 study, datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) versus investigator’s choice of chemotherapy (ICC) in patients with...

S. Wang, Q. Zhang, Z. Jiang et al. · 0 citations
Open access Sep 2026

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

This large collection of MBC cfDNA data is envisioned as an invaluable resource for the design and planning of future clinical trials, and cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials.

I. Leshchiner, A. Medford, J. Cha et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.